COMPANY

Solve Therapeutics

Location: Belmont, CA · source · Oct 13, 2026

Profile checked Oct 10, 2026

Keywords: SLV-154 SLR-108 SLX-1411

Funding and NIH signals

SEC Form D raise Raised $48.21M (Form D filed Nov 25, 2025). SEC Form D 0001231919-25-000548 (Nov 25, 2025)
Evidence (1 event)
- Nov 25, 2025 · SEC Form D 0001231919-25-000548
  Name of Issuer: Solve Therapeutics, Inc.; CIK: 1905252; Address: Belmont, CA; Submission type: D; Filing date: 2025-11-25; Industry Group: Biotechnology; Date of First Sale: 2025-11-14; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 120535618; Total Amount Sold: 48214232; Federal exemptions: 06b

Job counts as of Oct 18, 2026. All funding and NIH signals

Aug 4, 2026 Trial start Phase 1: SLR-108 PET Imaging in Subjects With Metastatic Solid Tumors source ↗
Aug 25, 2025 Trial start Phase 1: SLV-324 Treatment of Metastatic Solid Tumors source ↗
May 14, 2025 Trial start Phase 1: SLV-154 Treatment of Advanced Cancers source ↗

2027-05 (ESTIMATED) · Phase 1 · SLV-324 Treatment of Metastatic Solid Tumors · NCT07108114
2027-08 (ESTIMATED) · Phase 1 · SLV-154 Treatment of Advanced Cancers · NCT06771219
2028-01 (ESTIMATED) · Phase 1 · SLR-108 PET Imaging in Subjects With Metastatic Solid Tumors · NCT07728942

Estimated primary completion per ClinicalTrials.gov. Dates move.

Record	Title	Phase	Status	Start	Primary completion
NCT06771219	SLV-154 Treatment of Advanced Cancers	Phase 1	Recruiting	May 14, 2025	2027-08 (estimated)
NCT07728942	SLR-108 PET Imaging in Subjects With Metastatic Solid Tumors	Phase 1	Recruiting	Aug 4, 2026	2028-01 (estimated)
NCT07108114	SLV-324 Treatment of Metastatic Solid Tumors	Phase 1	Recruiting	Aug 25, 2025	2027-05 (estimated)